Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
Mem. Inst. Oswaldo Cruz
;
111(3): 218-221, Mar. 2016. tab, graf
Artículo
en Inglés
| LILACS
| ID: lil-777373
ABSTRACT
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruziquantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Tripanocidas
/
Trypanosoma cruzi
/
Enfermedad de Chagas
/
Nitroimidazoles
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio observacional
/
Estudio pronóstico
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Mem. Inst. Oswaldo Cruz
Asunto de la revista:
Medicina Tropical
/
Parasitología
Año:
2016
Tipo del documento:
Artículo
País de afiliación:
Argentina
Institución/País de afiliación:
Instituto Nacional de Parasitología Dr M Fatala Chabén/AR
Similares
MEDLINE
...
LILACS
LIS